Sarepta Therapeutics Surges to 259th in Trading Volume with $435 Million in Shares Exchanged Amid Major Restructuring

On July 17, 2025, Sarepta Therapeutics (SRPT) experienced a significant surge in trading volume, with a total of $435 million in shares exchanged, marking a 39.1% increase from the previous day. This surge placed Sarepta at the 259th position in terms of trading volume for the day. The stock price of Sarepta rose by 19.53%, marking the second consecutive day of gains, with a total increase of 20.65% over the past two days.

Sarepta's stock price surged following the company's announcement of a major restructuring plan. This plan includes the layoff of approximately 500 employees, which represents about 36% of its workforce. The restructuring is a response to two patient deaths and aims to cut costs and streamline operations.

The company also disclosed preliminary second-quarter results, showing total net product revenue of $513 million, with more than half coming from its gene therapy drug, Elevidys. This drug is used to treat Duchenne muscular dystrophy and has been a significant contributor to Sarepta's revenue.

Sarepta's restructuring plan includes pausing research on several drug programs and adding a black-box warning to Elevidys. This warning is the most serious safety alert a drug can have, indicating severe or potentially deadly complications. The company has agreed to this warning at the request of the US Food and Drug Administration (FDA).

Despite the challenges, Sarepta's CEO, Douglas Ingram, expressed confidence that Elevidys will remain on the market. The company is in dialogue with the FDA to address concerns and is proposing a new immune suppressant regimen for patients who are no longer able to walk, which could reduce the risk of liver complications.

Sarepta's restructuring plan is expected to contribute to an estimated $400 million in annual cost savings. The company also disclosed that the job cuts will help it maintain access to a $600 million revolving credit line and create cash flow that could help it repay a convertible note due in 2027.